GlassScriptPhysician profile
Lisa A Caffee
NPI 1548706807
$7,864.88
in general payments reported to CMS, 2019-2025
40 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,282 · 2022: $1,515 · 2023: $1,179 · 2024: $1,807 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,957 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,957.21 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,438.18 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,143.65 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Janssen Pharmaceuticals, INC | $350.48 | 2021-2024 | Spravato |
| Novo Nordisk INC | $334.04 | 2022-2024 | Wegovy |
| Neurocrine Biosciences, INC. | $333.59 | 2021-2025 | |
| Inspire Medical Systems, INC. | $324.33 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $300.80 | 2023-2024 | Auvelity, Sunosi |
| Lilly USA, LLC | $269.06 | 2021-2025 | Mounjaro, Kisunla |
| Avanir Pharmaceuticals, INC. | $267.91 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $263.39 | 2021-2023 | |
| Sk Life Science, INC. | $256.69 | 2022-2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $250.00 | 2023-2025 | |
| Gilead Sciences, INC. | $147.32 | 2021-2023 | Epclusa |
| Urovant Sciences INC | $124.99 | 2022 | |
| Eisai INC. | $124.94 | 2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Caffee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.